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Background: Oxidized low-density lipoprotein (LDL) plays central roles in the formation and progression of
atherosclerotic lesions. Malondialdehyde (MDA)-modified LDL (MDA-LDL) is speculated to be generated as a
result of oxidative stress in the human body. Because both amlodipine and atorvastatin have been reported to
reduce oxidative stress, it is expected that both drugs would have a favorable influence to reduce oxidative
stress.
Objective: The objective of this study was to investigate the effects of a single pill of amlodipine (5 mg)/atorvastatin
(10 mg) on oxidative stress, blood pressure/lipid control and adherence to medication in patients with type 2 diabetes.
Methods: This combination tablet was administered to 29 patients (16 male), and MDA-LDL, blood pressure, lipid
profile, renal/liver function, CPK, hs-CRP, adiponectin, BNP, and HbA1c were measured at baseline, 6, and 12 months,
and baPWV and mean IMT were measured at baseline and 12 months. Medication adherence was examined using a
questionnaire at 6 months.
Results: MDA-LDL was decreased significantly. LDL-C, TG, and Cr were significantly decreased at 6 and 12 months
compared with baseline. eGFR was increased at 6 months, and urinary albumin/creatinine ratio was decreased at
12 months. BNP was decreased at 6 and 12 months, and adiponectin was increased at 12 months. Both mean IMT and
baPWV were significantly decreased. The results of the questionnaire showed that 93% of patients were satisfied with
this medication. No severe adverse event was observed.
Conclusion: This combination tablet controlled both hypertension and dyslipidemia well in type 2 diabetic patients.
The deceases in mean IMT and baPWV might suggest the improvement of atherosclerosis by this medication, which
could be caused by the reduction of oxidative stress measured by MDA-LDL. In addition, this medication is expected to
improve medication adherence.
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Oxidized low-density lipoprotein (LDL), which is produced
through modification of LDL by oxidation, plays central
roles in the formation and progression of atherosclerotic le-
sions [1]. Malondialdehyde (MDA)-modified LDL (MDA-
LDL), a representative oxidized LDL [2], is speculated to be
generated as a result of oxidative stress in the human body.
It is suggested that MDA-LDL is involved in many pro-
cesses of atherosclerosis such as vascular intima injury and
foam cell formation [3,4]. Therefore, MDA-LDL has
attracted attention as a risk factor for macrovascular dis-
ease, such as ischemic heart disease and cerebral infarction.
Investigation of diabetic patients with a history of coron-
ary heart disease has shown that those with increased
plasma MDA-LDL concentration have a significantly higher
risk of coronary heart disease [5]. Moreover, it has been
shown that the risk of restenosis after percutaneous coron-
ary intervention is high if the concentration of MDA-LDL
is elevated [6]. It is reported that MDA-LDL concentration
in patients with cerebral infarction is significantly higher
than that in those without, at any age [7]. In addition, type
2 diabetes mellitus per se is an important risk factor for
macrovascular disease irrespective of the history of coron-
ary heart disease or cerebrovascular disease [8]. Therefore,
it is suggested that measurement of the serum concentra-
tion of MDA-LDL would be useful for the prevention of
coronary heart disease and cerebrovascular disease in pa-
tients with type 2 diabetes mellitus.
Both amlodipine, which is used to treat hypertension
and angina pectoris, and atorvastatin, which is used to
treat hypercholesterolemia/familial hypercholesterolemia,
have been reported to reduce oxidative stress [9]. There-
fore, it is expected that both drugs would have a favorable
influence to reduce oxidative stress. Moreover, there is ac-
cumulating evidence that these medications can be used
for the prevention of coronary heart disease and cerebral
infarction [10-13].
In this study, we prospectively investigate the impact
of combination therapy with amlodipine and atorva-
statin on plasma MDA-LDL level in patients with type 2
diabetes mellitus and concomitant hypertension and
hypercholesterolemia. We used a fixed combination
tablet containing 5 mg amlodipine and 10 mg atorva-
statin. This study hypothesizes that simplification of pa-
tients’ prescribed medication by using a combination
tablet will improve medication adherence. Therefore, in
this study, a questionnaire survey about medication ad-
herence was also conducted.
Subjects and methods
Subjects
The subjects were 29 Japanese outpatients with type 2 dia-
betes (16 men and 13 women) with complications of
hypertension and hypercholesterolemia aged 20 years orolder. Patients who could not achieve the lipid control goal
of the Japan Atherosclerosis Society (JAS) 2012 Guidelines
for prevention of atherosclerotic cardiovascular disease
(LDL-cholesterol (LDL-C) < 100 mg/dl for patients with
prior coronary heart disease and LDL-C < 120 mg/dl for pa-
tients without prior coronary heart disease) [14] and/or
who could not achieve the blood pressure-lowering goal of
the 2009 Japanese Society of Hypertension guidelines for
the management of hypertension (<130/80 mmHg) [15] in
spite of taking a statin and/or calcium channel blocker for
at least three months were enrolled.
Methods
MDA-LDL, blood pressure, LDL-C, high-density lipo-
protein cholesterol (HDL-C), triglyceride (TG), serum
creatinine (Cr), estimated glomerular filtration ratio
(eGFR), urinary albumin-creatinine ratio (ACR), aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), γ-glutamyl transferase (GTP), creatine phospho-
kinase (CPK), high-sensitivity C-reactive protein (hs-
CRP), adiponectin, brain natriuretic peptide (BNP) and
glycosylated hemoglobin A1c (HbA1c) were measured
at baseline and 6 and 12 months after the start of ad-
ministration of this combination tablet and compared.
MDA-LDL was measured using an enzyme-linked im-
munosorbent assay as reported previously [6,16]. LDL-C
was calculated using the Friedewald formula (LDL-C = total
cholesterol (TC)-HDL-C-TG/5). ACR was measured by a
turbidimetric immunoassay with a Superior-Microalbumin
kit (Daiichi Pharmaceutical Co., Tokyo, Japan) and the Jaffé
reaction, using an automated analyzer. hs-CRP was mea-
sured by a latex particle-enhanced immunoassay with the
nephelometry method (LABOSPECT 008; Hitachi, Tokyo,
Japan), using an hs-CRP kit from Mitsubishi Chemical
Medicine (Tokyo, Japan). BNP was measured by a fluores-
cence enzyme immunoassay, using a monoclonal antibody
(E-test, Tosoh II BNP; Tosoh, Tokyo, Japan). Adiponectin
was measured by a latex particle-enhanced immunoassay
as reported previously [17]. HbA1c was determined by
HPLC (Toso, Tokyo, Japan) and presented as the equiva-
lent National Glycohemoglobin Standardization Program
(NGSP) value.
Brachial-ankle pulse wave velocity (baPWV) and mean
intima-media thickness (IMT) were measured at baseline
and 12 months after the start of administration and com-
pared. baPWV was measured after 5 min of bed rest using
a BP-203RPE III (form PWV/ABI) device (Omron Health-
care, Kyoto, Japan). IMT was measured by ultrasonography
B-mode imaging, using a PowerVision® 6000 ultrasound
machine (Toshiba, Tokyo, Japan).
During the study period, the type and dose of medica-
tions that might influence glycemic, blood pressure and/or
lipid control were not changed in principle. We verified eli-
gibility of the patients at outpatient medical examinations
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as instructed by the doctors in charge.
In order to investigate medication adherence to this
combination tablet, we conducted a questionnaire survey.
The questionnaire consisted of questions about 1) the de-
gree of satisfaction with taking the combination tablet, 2)
reason(s) why the patient thinks it is good to take the
combination tablet, 3) desire to continue taking the com-
bination tablet in the future, and 4) feelings about the re-
duction in the number of tablets the patient is taking.
They wrote the answers to the multiple choice questions
themselves.
In order to investigate the effects of patient characteris-
tics on medical adherence, we performed multivariate ana-
lyses. We scored the results of the questionnaire as
follows: ‘Do you think it is good to take this combination
tablet?’: very good 3, good 2, not good 1; ‘Do you want to
continue taking this combination tablet?’: yes, very much
4, I think so 3, not very much 2, absolutely not 1; ‘Do you
think that even a decrease in one medication is a good
thing?’: yes, very much 4, I think so 3, not very much 2, I
completely disagree 1. Then, stepwise regression analyses
were performed using the following factors as independ-
ent variables: gender (men = 1, women = 2), age, duration
of diabetes, BMI, and baseline HbA1c.
This study was approved by the ethical committee of
Keio University School of Medicine. Doctors gave the pa-
tients a sufficient explanation of this clinical study. After
confirming that the patients understood and agreed to
take part, written informed consent was obtained.Table 1 Patient characteristics at baseline (n = 29)
Gender (n) Male 16 Female 13
Age (years) 58.9±11.0
BMI (kg/m2) 26.2±5.4









The results are shown as mean ± standard deviation, or number of patients.
Each patient belongs to only one group of diabetic agent.
OHA: oral hypoglycemic agent.Statistical analysis
Results were expressed as mean ± standard deviation.
Data analyses were performed using the JMP® software
package, version 6 (SAS Japan Institute Ltd., Tokyo,
Japan) for Windows®. Paired t-test was used to assess the
significance of differences between values obtained be-
fore and 6 and 12 months after the start of administra-
tion of the combination tablet. Values of p < 0.05 were
considered statistically significant (two-tailed analysis).
Results
Baseline characteristics of the patients are shown in Table 1.
Age, body mass index, duration of diabetes and HbA1c
were 58.9±11.0 years, 26.2±5.4 kg/m2, 14.4±6.2 years, and
8.3±1.6%, respectively. Many patients had complications of
micro- and macrovascular disease.
As shown in Figure 1, after administration of the combin-
ation tablet, MDA-LDL decreased significantly compared
with baseline (69.2±25.7 at baseline→59.3±18.3 at 6 months
(p < 0.05)→51.4±21.4 U/L at 12 months (p < 0.01)). Both
systolic and diastolic blood pressure decreased significantly
(systolic: 150.2±12.2 at baseline→136.2±17.4 at 6 months
(p < 0.01)→131.5±10.2 mmHg at 12 months (p < 0.01), dia-
stolic: 87.3±9.2 at baseline→82.0±9.3 at 6 months (p <
0.01)→78.0±6.6 mmHg at 12 months (p < 0.01)). LDL-C
decreased significantly from 110.8±33.7 mg/dl at base-
line to 82.3±26.7 mg/dl at 6 months (p < 0.01), and to
81.3±25.1 mg/dl at 12 months (p < 0.01). HDL-C did
not change significantly (48.9±12.7 mg/dl at base-










































Figure 1 Change in plasma MDA-LDL concentration. The results
are shown as mean±standard deviation. Comparison with the value
before administration of the combination tablet. *p < 0.05, **p < 0.01
(paired t-test).
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cantly (193.9±127.9 mg/dl at baseline→144.7±71.0 mg/dl
at 6 months (p < 0.05)→151.2±91.6 mg/dl at 12 months
(p < 0.01)).
Compared with baseline, serum Cr was decreased sig-
nificantly at both 6 and 12 months (0.77±0.19 mg/dl at
baseline→0.73±0.17 mg/dl at 6 months (p < 0.01)→0.74±
0.19 mg/dl at 12 months (p < 0.05)), and eGFR was in-
creased significantly at 6 months (77.0±30.4 at base-
line→80.2±27.4 at 6 months (p < 0.01)→78.6±25.0 ml/
min/1.73 m2 at 12 months). ACR was decreased signifi-
cantly at 12 months (67.6±118.4 at baseline→42.9±70.5 at
6 months→39.5±67.2 mg/gCr at 12 months (p < 0.05)).
As shown in Table 2, AST, ALT, γGTP, CPK, hs-CRP,
and HbA1c did not change significantly during the ob-
servation period.
As shown in Figure 2, BNP was significantly decreased at
both 6 and 12 months (19.5±14.0 at baseline→15.4±12.5 at
6 months (p < 0.01)→15.3±11.2 pg/ml at 12 months (p <
0.01)), and adiponectin was increased at 12 months (7.64±
4.49 at baseline→7.82±4.73 at 6 months→8.15±5.25 μg/ml
at 12 months (p < 0.05)).Table 2 Changes in clinical parameters







The results are shown as mean ± standard deviation.
No parameter showed a significant change during the course of this study.As shown in Figure 3, compared with baseline, both
baPWV and mean IMT improved significantly (baPWV:
1768.0±477.4 at baseline→1689.9±389.5 cm/sec at 12months
(p < 0.05), mean IMT: 0.91±0.21 at baseline→0.82±0.24 mm
at 12 months (p < 0.01)).
The results of the questionnaire survey are shown in
Table 3. Answers were obtained from 27 patients. Of the
patients, 93% (25/27) were satisfied with this combination
tablet (3a). The most common reason for satisfaction was
that “LDL-C was decreased sufficiently”. The second most
common reason was that “blood pressure was decreased
sufficiently” (3b).
Almost all (26/27) patients answered that they wanted
to continue taking this medication (3c), and 89% (24/27)
answered that even a decrease of one tablet is a good
thing (3d).
Stepwise regression analyses demonstrated that none of
the factors investigated was identified as an independent
determinant of the scores of three questions (1): gender β =
0.15, p = 0.54; age β = −0.20, p = 0.58, duration of diabetes
β = 0.04, p = 0.90, BMI β =−0.25, p = 0.30, baseline HbA1c
β = 0.22, p = 0.45, 3): gender β = 0.12, p = 0.60, age β = 0.47,
p = 0.14, duration of diabetes β = −0.32, p = 0.30, BMI β =
0.068, p = 0.78, baseline HbA1c β = 0.45, p = 0.13; 4): gender
β = 0.24, p = 0.33, age β = −0.61, p = 0.086, duration of dia-
betes β = 0.35, p = 0.31, BMI β = −0.042, p = 0.87, baseline
HbA1c β = −0.29, p = 0.35).
No severe adverse event occurred, and all 29 patients
could continue taking this combination tablet.
Discussion
After the administration of a fixed combination tablet con-
taining 5 mg amlodipine and 10 mg atorvastatin, blood
pressure, LDL-C, TG, and MDA-LDL were significantly
improved in type 2 diabetic patients with hypertension and
dyslipidemia. In addition, baPWV and mean IMT, which
are markers of atherosclerosis, also improved.
The achieved LDL-C, systolic and diastolic blood
pressure were 81.3±25.1 mg/dl,131.5±10.2 mmHg, and
78.0±6.6 mmHg, respectively. LDL-C (<120 mg/dl) and
diastolic blood pressure (<80 mmHg) reached the target


























































Figure 2 Changes in plasma concentration of BNP and adiponectin. The results are shown as mean ± standard deviation. Comparison with
the value before administration of the combination tablet. *p < 0.05, **p < 0.01 (paired t-test).
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shown that this combination tablet could control both
hypertension and hypercholesterolemia, which are the two
major risk factors for atherosclerosis. Taken together with
the report that thickening of IMT is an independent, sig-
nificant predictor of cerebral infarction and coronary ar-
tery disease [18,19], this medication is considered to be
very useful for the prevention of macrovascular complica-
tions in type 2 diabetic patients.
In the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid
Lowering Arm (ASCOT-LLA), it was shown that treating



















Figure 3 Changes in baPWV and mean IMT. The results are shown as m
administration of the combination tablet. *p < 0.05, **p < 0.01 (paired t-testin hypertensive patients taking antihypertensive medication
“at high risk”, even though their total cholesterol was
250 mg/dl or less [13]. Patients “at high risk” means that
they have several characteristics including old age (55 years
or more), male, smoking habit, type 2 diabetes, microalbu-
minuria, and left ventricular hypertrophy. Therefore, the re-
sults of ASCOT-LLA can be applied to many patients we
encounter in daily clinical settings. This indicates the use-
fulness of treating not only hypertension but also dyslipid-
emia at the same time in hypertensive patients.
Another analysis of ASCOT-LLA showed that the inci-




















ean ± standard deviation. Comparison with the value before
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Table 3 Results of questionnaire survey on medication
adherence





b. Reason(s) why you think that it was good to take this
combination tablet
LDL-C was decreased sufficiently 12
Blood pressure was decreased sufficiently 10
Tablet is small and easy to swallow 8
I do not have to discriminate morning and evening doses 5
Number of times taking medication is reduced 5
Number and dose of medications taken in one day is reduced 6
Number and dose of medications taken at one time is reduced 8
c. Do you want to continue taking this combination tablet?
Yes, very much 12
I think so 14
Not very much 0
Absolutely not 0
No answer 1
d. Do you think that even a decrease in one medication is a
good thing?
Yes, very much 19
I think so 5
Not very much 1
I completely disagree 0
I have no idea 2
N: number of answers.
3b: Multiple answers were allowed.
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pared with patients treated with atenolol and atorvastatin,
even though there was no significant difference in blood
pressure, TC, or LDL-C between the two patient groups
[20]. Consequently, from the perspective of cardiovascular
event prevention, it was suggested that the combination of
amlodipine and atorvastatin might have high efficacy and
that this fixed-dose combination tablet is very important
because patients can take both amlodipine and atorva-
statin by taking only one tablet.
Because MDA-LDL is thought to be involved in many
steps of atherosclerosis, it is a promising candidate as a
risk factor for atherosclerosis other than established risk
factors such as hypertension, diabetes, and LDL-C. It
has been shown that the plasma concentration of MDA-
LDL is increased in patients with unstable carotid artery
plaques [21]. In the present study, this combination tab-
let decreased MDA-LDL, which suggests the possibility
that this medication might directly intervene in manyprocesses of atherosclerosis. Taking these findings together
with the result that this combination tablet improved
baPWV and mean IMT, this medication is thought to be
highly promising as an anti-atherosclerosis drug.
MDA-LDL has been reported to exert direct cytotoxicity
on endothelial cells, to promote synthesis and secretion of
adhesion molecules, to increase platelet aggregation and
monocyte adhesion, and to enhance foam cell formation
in atherosclerotic lesions, all of which lead to remodeling
of vessel walls [3,4]. The level of circulating MDA-LDL is
reported to be elevated in patients with diabetes [22]. The
mechanisms underlying the increase in MDA-LDL in dia-
betic patients are not clear, although enhancement of lipid
peroxidation might be involved [23]. The main causes
of death of diabetic patients are macrovascular diseases
caused by severe atherosclerosis. Considering this, the ob-
servation that this combination tablet decreased MDA-
LDL significantly might have clinical significance from the
perspective of macrovascular disease prevention. Measure-
ment of MDA-LDL, especially in diabetic patients, is ex-
pected to have a clinical impact.
During the observation period, Cr and ACR decreased,
eGFR increased, and BNP decreased significantly. All of
these results may reflect the reno- and cardio- protective ef-
fects of this combination tablet. Although statins have been
reported to possess a reno-protective effect, it was shown
that the reno-protective effect of atorvastatin is stronger
than that of other statins [24]. Atorvastatin has been shown
to improve eGFR and Cr clearance in several sub-analyses
from large scale clinical trials such as the Collaborative
Atorvastatin Diabetes Study (CARDS) [25], the Treating to
New Targets (TNT) [26], and the Greek atorvastatin and
coronary heart disease evaluation (GREACE) [27].
As one of the mechanisms underlying the reno-
protective effect of atorvastatin, the possibility that atorva-
statin might suppress podocyte injury was reported recently
[28]. In a sub-analysis of TNT, administration of atorva-
statin significantly reduced hospitalization due to heart fail-
ure [29]. Therefore, as a mechanism of BNP lowering in
this study, there is a possibility that the pleiotropic effect of
atorvastatin was added to the blood pressure-lowering
effect of amlodipine.
In the present study, it was shown that the concentra-
tion of adiponectin was increased after 12 months of ad-
ministration of this combination tablet. It is reported that
when both atorvastatin and amlodipine were administered
in patients with coronary heart disease, hypertension and
dyslipidemia, the plasma concentration of adiponectin in-
creased [30]. In this study, it is also reported that the in-
crease in adiponectin concentration and improvement
ratio of vascular intima function evaluated by flow-
mediated vasodilation (FMD) method were correlated
[30]. Although the underlying mechanism of the improve-
ment of baPWV and mean IMT in this study is not clear,
Tanaka et al. Diabetology & Metabolic Syndrome 2014, 6:56 Page 7 of 8
http://www.dmsjournal.com/content/6/1/56increase in adiponectin might be involved, through an anti-
atherosclerotic action, in addition to blood pressure lower-
ing by amlodipine and LDL-C lowering by atorvastatin.
An improvement in medication adherence leads to an
increase in the direct benefit of the medication. It has
been reported that as the number of drugs taken in one
day increases, medication adherence deteriorates, and
that as the number of drugs and times of medication de-
crease, medication adherence improves [31]. Moreover,
it is reported that medication adherence is improved by
using a combination tablet [32].
The questionnaire survey about medication adherence
in the present study showed high satisfaction with the
combination tablet. As a reason for this, many patients
stated a sufficient decrease in LDL-C and blood pressure.
It is important that patients evaluated both the decrease in
number of tablets and the drug efficacy, that is, improve-
ment in blood pressure and dyslipidemia highly. Because
89% (24/27) of patients answered that even a decrease in
one tablet is a good thing, the medication adherence to
this combination tablet might be very good. Stepwise re-
gression analyses showed that none of gender, age, dur-
ation of diabetes, BMI, and baseline HbA1c influenced the
results of the questionnaire survey. This might suggest the
possibility that this medication improves medication ad-
herence in many patients with a wide variety of back-
grounds. However, this should be confirmed by larger
scale studies containing a control group. It is reported that
if medication adherence is high for 1–2 years after initi-
ation, medication adherence will continue to be high
thereafter [33]. Therefore, it is expected that the partici-
pants in this clinical trial will continue to take this com-
bination tablet in the future.
This study included many patients with a long dur-
ation of diabetes mellitus or poor glycemic control.
Many patients had complications of obesity, diabetic mi-
croangiopathy, and macroangiopathy. Many patients took
an antihypertensive, antidiabetic, or antiplatelet drug. Not-
withstanding, no severe adverse event occurred, and all 29
patients could continue taking this combination tablet.
Liver function, CPK, and HbA1c did not deteriorate dur-
ing the course of the study. Therefore, the safety of this
medication appears to be confirmed in high risk patients.
There are some limitations of this study. Firstly, the
number of patients included was small. Secondly, this
was a single arm study and did not have a control. Fi-
nally, the results of our study may not be applicable to
the general population or to patients with type 2 dia-
betes in a primary care setting, because patients who at-
tend university hospitals are selected patients.
Conclusion
It was shown that a single-pill of amlodipine (5 mg)/
atorvastatin (10 mg) could control both blood pressureand lipid profile well in type 2 diabetic patients with com-
plications of hypertension and dyslipidemia. The deceases
in mean IMT and baPWV might suggest the improvement
of atherosclerosis by this medication, which could be ex-
plained at least in part by the reduction of oxidative stress
measured by MDA-LDL. This medication is expected to
prevent cardiovascular events through a decrease of oxida-
tive stress and improvement of medication adherence.
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